Piper Jaffray has a Neutral rating on Santarus Inc. SNTS and a $3.50 price target after the company presented at a Piper Jaffray conference.
In a note sent to clients, Piper Jaffray writes, "Yesterday, Santarus presented at the Piper Jaffray Healthcare Conference. Management provided additional color on its newest commercially available product, Cycloset (bromocriptine), as well as its pipeline, including budesonide MMX for ulcerative colitis (UC), rifamycin SV MMX for traveler's diarrhea (TD) and potentially hepatic encephalopathy (HE), and Rhucin, a recombinant C1 inhibitor for the treatment of acute hereditary angioedema (HAE). Though these represent opportunities for longer-term value creation, we continue to believe cash flows for the 2011-2012 will be relatively modest, and would therefore remain on the sidelines. We reiterate our Neutral rating and $3.50 PT."
Shares of SNTS closed at $2.76 yesterday, down 1 cent.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsDiversified BanksFinancialsHealth CareHealth Care SuppliesPharmaceuticalsPiper JaffrayUtilities
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in